PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J. Rossi, Ph.D., a pioneer and one of the world leaders in the field of RNAi discovery and development, has joined majority owned subsidiary Calando Pharmaceuticals, Inc. as a senior advisor. Dr. Rossi, who is also one of the co-founders of Calando, will be the first member of Calando’s new Scientific Advisory Board. Calando is building its SAB to help guide further development of CALAA-01 as the Phase 1 trial nears completion, contribute to partnering activities, initiate new clinical candidates, and expand the RONDEL™ delivery system.
